Clinical Trial Update: Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on safety, reactogenicity, and immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Phase 2 completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Typhoid Fever

Drugs mentioned

• Vi-DT Typhoid Conjugate Vaccine (Vi-diphtheria toxoid conjugate vaccine)

Snippet

Sponsor: International Vaccine Institute | Conditions: Typhoid | Phase 2 | Status: COMPLETED